Skip to main content
Equibles
MDLN logo

MDLN · Medline Inc. · Metrics

Track MDLN — free

Use MDLN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDLN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$34.09 -0.79 (-2.26%) At close · Oct 23
Russell 1000 member Rebalance outlook locked
Customer concentration — key customers 74% of revenue

Key customers — 74% of revenue (the year ended December 31, 2025)

“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”

Key customers — 69% of revenue (the year ended December 31, 2025)

“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”

5 customers — 11.3% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, our top five U.S. customers represented approximately $3.2 billion (or 11.3%) of our net sales.”
View the 10-K filed Feb 25, 2026
Market Cap
$44.82B
Shares
1.31B
Volume · Oct 23 7.44M Avg daily vol (3M) 7.97M

MDLN metrics

74 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$34.09
Market cap
$44.82B

Price action

20 metrics
Price change (1W)
-5.2%
Price change (30D)
-1.8%
Price change (3M)
-12.0%
Price change (6M)
-23.8%
Price change (YTD)
-18.8%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
44.2%
Annualized volatility (3M)
45.9%
Beta
0.6
RSI (14D)
41.4
Price vs SMA 50
-1.7%
Price vs SMA 200
-14.5%
Avg volume (3M)
7.97M
Relative volume
0.9
Average dollar volume
$280.24M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
1.31B

Valuation

12 metrics
P / E (TTM)
41.5
Trailing earnings · reciprocal yield 2.4%
PEG ratio
—
EV / revenue
1.8×
reciprocal yield 54.7%
EV / EBITDA
19.3×
reciprocal yield 5.2%
EV / EBIT
30.1×
reciprocal yield 3.3%
P / sales
1.5×
reciprocal yield 66.8%
P / book
3.9
reciprocal yield 25.8%
FCF yield
3.4%
TTM · current market cap
Buyback yield
0.0%
P / FCF
29.0
reciprocal yield 3.4%
P / operating cash flow
22.5
reciprocal yield 4.4%
Earnings yield
2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
26.2%
Operating margin
6.1%
Trailing 12 months
Net margin
4.1%
Gross profit (TTM)
$7.84B
Operating profit (TTM)
$1.82B
Net income (TTM)
$1.08B
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
5.2%
Effective tax rate
18.3%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+11.6%
Year over year
Net income growth YoY
-57.8%
Revenue (TTM)
$29.94B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
9.6%
Return on assets
2.8%
Debt / equity
1.1
Current ratio
4.3
EBITDA (TTM)
$2.84B
Free cash flow (TTM)
$1.55B
Quick ratio
2.6
Interest coverage
2.3
Net debt / EBITDA
3.5
Return on invested capital
6.9%
Trailing 12 months
Net cash
−$9.90B
Latest balance sheet
Cash & equivalents
$2.33B
Total assets
$39.35B
Total debt
$12.58B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.99B
Capital expenditures (TTM)
$446.00M
R&D (TTM)
—
SG&A (TTM)
$4.90B
Stock compensation (TTM)
$94.00M
R&D / revenue
—
Stock compensation / revenue
0.3%

Ownership (13F)

9 metrics
13F filers
411
13F filer change QoQ
+95
Institutional ownership
65.1%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+10.5%
Holder tenure
2.8
Price vs estimated holder cost
-4.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.7%

Short interest

3 metrics
Short interest
4.0%
Latest settlement · 5.1 days to cover
Days to cover
5.1d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 2046386 CUSIP 58507V107 13F (30d) 76 filings 72 filers Visit website Investor relations